Sopharma AD (BUL:SFA)
Bulgaria · Delayed Price · Currency is BGN · Price in EUR 1.900
0.00 (0.00%)
At close: Jul 10, 2026
Sopharma AD Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,385 | 1,335 | 1,091 | 958.79 | 850.09 | 819.88 |
Other Revenue | 12.94 | 11.71 | 9.67 | 6.92 | 4.35 | 4.11 |
| 1,398 | 1,347 | 1,101 | 965.71 | 854.43 | 824 | |
Revenue Growth (YoY) | 20.06% | 22.31% | 14.02% | 13.02% | 3.69% | 11.47% |
Cost of Revenue | 1,057 | 1,027 | 864.17 | 751.73 | 667.67 | 646.57 |
Gross Profit | 341.26 | 319.77 | 236.88 | 213.98 | 186.77 | 177.42 |
Selling, General & Admin | 209.76 | 198.34 | 160.2 | 128.43 | 110.19 | 113.52 |
Other Operating Expenses | 11.85 | 11.98 | 5.76 | 9.2 | 6.01 | 3.73 |
Operating Expenses | 264.58 | 250.79 | 196.44 | 166.27 | 142.88 | 145.99 |
Operating Income | 76.68 | 68.99 | 40.44 | 47.7 | 43.89 | 31.44 |
Interest Expense | -11.39 | -11 | -6.64 | -5.61 | -3.08 | -5.52 |
Interest & Investment Income | 3.18 | 1.96 | 1.29 | 1.75 | 1.63 | 2.49 |
Earnings From Equity Investments | 18.58 | 19.6 | 13.24 | 12.51 | 11.57 | 6.18 |
Currency Exchange Gain (Loss) | -1.66 | -0.71 | -2.96 | -0.71 | -0.06 | 1.17 |
Other Non Operating Income (Expenses) | 3.41 | -0.71 | -1.49 | -1.31 | -1.63 | -0.48 |
EBT Excluding Unusual Items | 88.8 | 78.13 | 43.88 | 54.34 | 52.32 | 35.29 |
Impairment of Goodwill | - | - | - | - | -4.91 | - |
Gain (Loss) on Sale of Investments | - | - | -0.06 | 0.49 | -0.81 | 0.08 |
Gain (Loss) on Sale of Assets | 0.38 | 0.26 | 0.67 | 2.32 | 1 | 19.44 |
Asset Writedown | -0.07 | -0.04 | -0.22 | -0.74 | -4.33 | -5.29 |
Legal Settlements | 0.52 | 0.51 | 2.04 | - | - | - |
Other Unusual Items | 1.59 | 1.57 | 0.89 | 0.45 | 0.22 | 0.38 |
Pretax Income | 91.21 | 80.43 | 47.2 | 56.85 | 43.49 | 49.9 |
Income Tax Expense | 7.04 | 8.01 | 5.97 | 5.79 | 4.47 | 3 |
Earnings From Continuing Operations | 84.18 | 72.42 | 41.23 | 51.06 | 39.02 | 46.89 |
Minority Interest in Earnings | -3.54 | -4.12 | -2.11 | -1.99 | -2.66 | -1.13 |
Net Income | 80.63 | 68.3 | 39.12 | 49.07 | 36.36 | 45.77 |
Net Income to Common | 80.63 | 68.3 | 39.12 | 49.07 | 36.36 | 45.77 |
Net Income Growth | 81.50% | 74.61% | -20.29% | 34.98% | -20.56% | 200.39% |
Shares Outstanding (Basic) | 350 | 343 | 493 | 392 | 364 | 376 |
Shares Outstanding (Diluted) | 356 | 343 | 494 | 415 | 375 | 376 |
Shares Change (YoY) | -31.67% | -30.63% | 19.21% | 10.64% | -0.36% | -0.31% |
EPS (Basic) | 0.23 | 0.20 | 0.08 | 0.13 | 0.10 | 0.12 |
EPS (Diluted) | 0.23 | 0.20 | 0.08 | 0.12 | 0.10 | 0.12 |
EPS Growth | 172.92% | 153.50% | -33.17% | 21.08% | -19.76% | 199.73% |
Free Cash Flow | 19.4 | -13.53 | 21.96 | 10.55 | 46.38 | -49.25 |
Free Cash Flow Per Share | 0.05 | -0.04 | 0.04 | 0.03 | 0.12 | -0.13 |
Dividend Per Share | - | - | 0.027 | 0.169 | 0.102 | - |
Dividend Growth | - | - | -84.29% | 65.03% | - | - |
Gross Margin | 24.41% | 23.75% | 21.51% | 22.16% | 21.86% | 21.53% |
Operating Margin | 5.49% | 5.12% | 3.67% | 4.94% | 5.14% | 3.82% |
Profit Margin | 5.77% | 5.07% | 3.55% | 5.08% | 4.25% | 5.55% |
Free Cash Flow Margin | 1.39% | -1.00% | 1.99% | 1.09% | 5.43% | -5.98% |
EBITDA | 114.22 | 105.19 | 67.01 | 65.37 | 60.82 | 47.99 |
EBITDA Margin | 8.17% | 7.81% | 6.09% | 6.77% | 7.12% | 5.82% |
D&A For EBITDA | 37.54 | 36.21 | 26.57 | 17.67 | 16.92 | 16.55 |
EBIT | 76.68 | 68.99 | 40.44 | 47.7 | 43.89 | 31.44 |
EBIT Margin | 5.49% | 5.12% | 3.67% | 4.94% | 5.14% | 3.82% |
Effective Tax Rate | 7.72% | 9.96% | 12.65% | 10.18% | 10.28% | 6.02% |
Advertising Expenses | - | 0.96 | 1.01 | 1.16 | 11.27 | 14.02 |